QuellTX Ltd
QuellTX Ltd is a London-based clinical-stage biotechnology company focused on developing engineered regulatory T cell (Treg) therapies for immune-mediated diseases. Founded in 2019 by leading immunology experts, the company aims to transform the lives of individuals suffering from autoimmune and inflammatory diseases through pioneering therapies. Its lead asset, QEL-005, is currently being evaluated in the Phase 1/2 CHILL clinical trial.